Seres dou­bles down on a mi­cro­bio­me do-over as the FDA clears a make-or-break study

Seres CEO Roger Pomer­antz says he’s back on track.

Eight months af­ter the biotech in­dus­try’s lead­ing mi­cro­bio­me pro­gram de­railed in a dis­as­trous Phase II, Seres’ chief says he and his team per­suad­ed reg­u­la­tors at the FDA to sign off on a new study that could pro­vide piv­otal da­ta on his top pro­gram. And now he’ll dou­ble down on a tri­al that will once again roll the dice on a cut­ting-edge ef­fort to de­vel­op a gut-lev­el ther­a­py that can right a chal­leng­ing health wrong.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER